Market Cap | 30.38M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -28.37M | Forward P/E | -0.84 | EPS next Y | - | 50D Avg Chg | -25.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -31.00% |
Dividend | N/A | Price/Book | 0.86 | EPS next 5Y | - | 52W High Chg | -67.00% |
Recommedations | 2.00 | Quick Ratio | 2.17 | Shares Outstanding | 5.80M | 52W Low Chg | 53.00% |
Insider Own | 0.10% | ROA | -92.82% | Shares Float | 5.28M | Beta | 1.85 |
Inst Own | 14.53% | ROE | -189.52% | Shares Shorted/Prior | 62.61K/81.19K | Price | 7.97 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 372,934 | Target Price | 30.00 |
Oper. Margin | - | Earnings Date | Nov 18 | Volume | 6,924 | Change | -1.60% |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Brookline Capital | Hold | Dec 7, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Wijngaard Peter | Director Director | Nov 24 | Buy | 3.07 | 5,000 | 15,350 | 9,501 | 11/28/23 |
Wijngaard Peter | Director Director | Sep 15 | Buy | 5.57 | 3,000 | 16,710 | 4,501 | 09/20/23 |
Foster Robert T | CEO and Director CEO and Director | Sep 18 | Buy | 5.60 | 1,600 | 8,960 | 50,470 | 09/19/23 |
Foster Robert T | CEO,CSO and Director CEO,CSO and Director | Sep 15 | Buy | 5.40 | 1,600 | 8,640 | 48,870 | 09/18/23 |